In Singapore, a modern manufacturing facility is to be built by Chinese contract research, development and manufacturing organization (CRDMO) WuXi Biologics (HK: 2269).
The Hong Kong-listed company has already broken ground on the 13.5-hectare center at the Tuas Biomedical Park, which will eventually host integrated biologics research, development and manufacturing services.
WuXi is now one of the leading players in the contract research and manufacturing sector, inking major deals with companies including BioNTech (Nasdaq: BNTX) and GSK (LSE: GSK).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze